Anti-Tumor Activity of Modified Polypeptide HM-3
Author Information
Author(s): Liu Zhendong, Ren Yinling, Pan Li, Han-Mei Xu
Primary Institution: China Pharmaceutical University
Hypothesis
Can modifying the polypeptide HM-3 with different polyethylene glycols (PEG) improve its anti-tumor efficacy and extend its half-life?
Conclusion
The modified polypeptide SC-mPEG20k-HM-3 showed a low plasma clearance rate and high anti-tumor efficacy, making it a promising candidate for new anti-tumor drugs.
Supporting Evidence
- SC-mPEG20k-HM-3 had a tumor inhibition rate of 50.23%, which was higher than that of Taxol.
- The study demonstrated that SC-mPEG20k-HM-3 retained the anti-tumor activity of HM-3 better than other PEG-modified products.
- Modification with SC-mPEG20k extended the drug administration frequency from twice per day to once every two days.
Takeaway
Scientists made a special version of a cancer-fighting protein that lasts longer in the body and works better against tumors.
Methodology
The study involved modifying HM-3 with different PEGs and testing their anti-tumor effects in BALB/c mice.
Limitations
The study primarily focused on a limited number of PEG modifications and their effects on a specific cancer model.
Participant Demographics
BALB/c nude female mice, 4-5 weeks old, weighing approximately 20.9 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website